SciRhom raises €63.0M Series A round
15 July 2024· Martinsried, Germany· health, biotech, immunology, therapeutics, b2b, deep_hardware
The funding will be used to advance SciRhom's lead antibody candidate (SR-802) to clinical proof-of-concept for the treatment of autoimmune diseases such as inflammatory bowel disease (IBD) and rheumatoid arthritis.
Investors
LeadAndera Partners
Also participating
Bayern KapitalEurazeoPureos BioventuresF-Prime CapitalKurma PartnersHadean VenturesSD Venture CapitalHigh-Net-Worth Individuals
About SciRhom
Stage
Series A
Headquarters
Martinsried, Germany
Founded
2016
Team Size
21–50
Sectors
healthbiotechimmunologytherapeuticsb2bdeep_hardware